用于预防或治疗早产儿呼吸窘迫综合征的更高初始剂量表面活性剂
Higher initial doses of surfactant for the prevention or treatment of respiratory distress syndrome in preterm infants.
作者信息
Borys Franciszek, Sibrecht Greta, Mohammad Khuzaini Aliyyah, Fiander Michelle, Bruschettini Matteo, Soll Roger F
机构信息
II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.
Doctoral School, Poznan University of Medical Sciences, Poznan, Poland.
出版信息
Cochrane Database Syst Rev. 2025 Apr 28;4(4):CD016180. doi: 10.1002/14651858.CD016180.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of higher - compared with standard - initial doses of surfactant in high-risk preterm infants and preterm infants with respiratory distress syndrome.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估与标准初始剂量相比，高剂量表面活性剂对高危早产儿和患有呼吸窘迫综合征的早产儿的影响。
相似文献
1
Higher initial doses of surfactant for the prevention or treatment of respiratory distress syndrome in preterm infants.
Cochrane Database Syst Rev. 2025 Apr 28;4(4):CD016180. doi: 10.1002/14651858.CD016180.
2
Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome.
Cochrane Database Syst Rev. 2009 Jan 21(1):CD000141. doi: 10.1002/14651858.CD000141.pub2.
3
Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants.
Cochrane Database Syst Rev. 2015 Dec 21;2015(12):CD010249. doi: 10.1002/14651858.CD010249.pub2.
4
Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
Cochrane Database Syst Rev. 2007 Oct 17(4):CD006069. doi: 10.1002/14651858.CD006069.pub3.
5
Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
Cochrane Database Syst Rev. 2015 May 26(5):CD000144. doi: 10.1002/14651858.CD000144.pub2.
6
Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
Cochrane Database Syst Rev. 2015 Aug 24;8(8):CD000144. doi: 10.1002/14651858.CD000144.pub3.
7
Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD006180. doi: 10.1002/14651858.CD006180.pub2.
8
Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.
Cochrane Database Syst Rev. 2011 Jul 6(7):CD008309. doi: 10.1002/14651858.CD008309.pub2.
9
Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome.
Cochrane Database Syst Rev. 2023 Oct 26;10(10):CD013158. doi: 10.1002/14651858.CD013158.pub2.
10
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
Cochrane Database Syst Rev. 2001(2):CD000510. doi: 10.1002/14651858.CD000510.
本文引用的文献
1
Respiratory distress syndrome is associated with increased morbidity and mortality in late preterm births.
Am J Obstet Gynecol MFM. 2024 Jun;6(6):101374. doi: 10.1016/j.ajogmf.2024.101374. Epub 2024 Apr 5.
2
Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome.
Cochrane Database Syst Rev. 2023 Oct 26;10(10):CD013158. doi: 10.1002/14651858.CD013158.pub2.
3
European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update.
Neonatology. 2023;120(1):3-23. doi: 10.1159/000528914. Epub 2023 Feb 15.
4
Respiratory distress syndrome in preterm infants of less than 32 weeks: What difference does giving 100 or 200 mg/kg of exogenous surfactant make?
Pediatr Pulmonol. 2022 Sep;57(9):2067-2073. doi: 10.1002/ppul.25979. Epub 2022 May 27.
5
Diagnosis and management of bronchopulmonary dysplasia.
BMJ. 2021 Oct 20;375:n1974. doi: 10.1136/bmj.n1974.
6
Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018.
J Pediatr. 2022 Jan;240:66-71.e4. doi: 10.1016/j.jpeds.2021.08.075. Epub 2021 Sep 2.
7
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
8
Guidelines for surfactant replacement therapy in neonates.
Paediatr Child Health. 2021 Feb 1;26(1):35-49. doi: 10.1093/pch/pxaa116. eCollection 2021 Feb.
9
An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials.
J Clin Epidemiol. 2021 May;133:130-139. doi: 10.1016/j.jclinepi.2021.01.006. Epub 2021 Jan 18.
10
Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews.
J Clin Epidemiol. 2021 May;133:140-151. doi: 10.1016/j.jclinepi.2020.11.003. Epub 2020 Nov 7.
Zotero 插件